Zammarrelli WA 3rd, Ma W, Espino K, Gordhandas S, et al. Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer. Gynecol Oncol 2023;178:27-35.
PMID: 37748268